Intellia gains 38% in a month as additional positive phase III lonvo-z data and other pipeline progress boost investor optimism.

zacks.com - 2026-07-09 11:21:04

Gene-editing is a handy tool for developing sophisticated medicines. A new CRISPR molecule can destroy cells that express specific signals.

fool.com - 2026-07-08 05:45:00

CAMBRIDGE, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on July 1, 2026, it awarded inducement grants to thirteen new employees under Intellia's 2024 Inducement Plan, as amended, as a material inducement to employment.

globenewswire.com - 2026-07-06 16:05:00

It might pull it off, provided several things fall right in place.

fool.com - 2026-07-01 15:45:00

Fresh short‑interest data for late June shows a tightly packed group of mid‑ and large‑cap names where bearish positioning has reached extreme territory, setting the stage for violent moves if sentiment flips.

benzinga.com - 2026-06-29 10:35:25

Intellia Therapeutics is leveraging its strategic partnership with Regeneron to advance a deep pipeline of CRISPR-based gene editing therapies. Omeros recently entered the commercial stage with the FDA approval of Yartemlea and a significant development deal with Novo Nordisk.

fool.com - 2026-06-20 11:02:04

Stocks are mixed, with the Dow Jones Industrial Average (DJI) trading at fresh record highs once again

schaeffersresearch.com - 2026-06-17 12:03:00

There could be additional catalysts for this drugmaker over the next year.

fool.com - 2026-06-17 02:30:00

Intellia jumps after additional phase III HAELO data showed lonvo-z cut on-demand-treated attacks by 89% and moderate-to-severe episodes by 91%.

zacks.com - 2026-06-16 11:20:49

Intellia Therapeutics (NTLA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

zacks.com - 2026-06-16 09:45:15

Intellia Therapeutics, Inc. (NASDAQ:NTLA) stock is trading higher on Monday on additional positive findings from its global Phase 3 HAELO trial evaluating lonvo-z, its investigational CRISPR-based treatment for hereditary angioedema (HAE).

benzinga.com - 2026-06-15 09:39:58

CAMBRIDGE, Mass., June 13, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today presented additional positive results from the global Phase 3 HAELO clinical trial of lonvo-z (formerly NTLA-2002) for hereditary angioedema (HAE) in a late-breaking oral presentation at the European Academy of Allergy & Clinical Immunology (EAACI) Annual Congress 2026 in Istanbul, Türkiye. Results from the trial were simultaneously published in the New England Journal of Medicine. The presentation and publication can be accessed from the Scientific Publications and Presentations section of intelliatx.com.

globenewswire.com - 2026-06-13 07:30:00

Intellia Therapeutics (NTLA) reported earnings 30 days ago. What's next for the stock?

zacks.com - 2026-06-10 12:31:06

CAMBRIDGE, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on June 1, 2026, it awarded inducement grants to six new employees under Intellia's 2024 Inducement Plan, as amended, as a material inducement to employment.

globenewswire.com - 2026-06-05 16:05:00

CAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that data from the global Phase 3 HAELO clinical trial of lonvo-z (formerly known as NTLA-2002) in hereditary angioedema (HAE) will be presented in a late-breaking oral presentation at the European Academy of Allergy & Clinical Immunology (EAACI) Annual Congress 2026, taking place June 12-15 in Istanbul, Türkiye. Intellia will also have a poster presentation detailing the burdens experienced by HAE patients living outside the United States.

globenewswire.com - 2026-06-01 07:30:00

Intellia Therapeutics remains a Buy, driven by two pivotal in vivo gene therapy catalysts: Lonvo-Z for HAE and Nex-Z for ATTR amyloidosis. Lonvo-Z's Phase 3 data met all endpoints with an 87% attack reduction, but market reaction was muted due to safety concerns and the competitive landscape. The FDA lifted clinical holds on Nex-Z Phase 3 trials, enabling advancement in a $16.8bn ATTR market with a differentiated one-time treatment profile.

seekingalpha.com - 2026-05-31 08:45:00

NTLA gains momentum after positive phase III data for its CRISPR therapy, while ADMA faces pricing and inventory pressure in IG markets.

zacks.com - 2026-05-27 15:36:08

NTLA advances late-stage studies for nex-z and starts FDA filing for lonvo-z, positioning its pipeline for potential long-term growth.

zacks.com - 2026-05-19 12:56:07

Intellia Therapeutics, Inc. (NTLA) Presents at Bank of America Global Healthcare Conference 2026 Transcript

seekingalpha.com - 2026-05-12 21:40:48

Intellia cuts its Q1 loss, advances late-stage gene-editing programs and plans a 2027 launch for lonvo-z after strong phase III HAE data.

zacks.com - 2026-05-12 12:47:11

Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.92. This compares to a loss of $1.1 per share a year ago.

zacks.com - 2026-05-11 09:41:06

Presented positive Phase 3 HAELO topline clinical data for lonvo-z in HAE; initiated rolling BLA submission; anticipate U. S. launch in first half of 2027 Recently resumed patient screening in MAGNITUDE and MAGNITUDE-2 Phase 3 clinical trials of nex-z in ATTR-CM and ATTRv-PN, respectively Including proceeds from underwritten public offering in April, existing cash resources expected to fund operations at least into 2028 CAMBRIDGE, Mass.

globenewswire.com - 2026-05-11 07:30:00

CAMBRIDGE, Mass., May 11, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today reported business updates and financial results for the first quarter ended March 31, 2026.

globenewswire.com - 2026-05-11 07:30:00

Intellia Therapeutics (NTLA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

zacks.com - 2026-05-07 11:01:03

One of these stocks plummeted 49% on Tuesday.

fool.com - 2026-05-06 10:12:00

CAMBRIDGE, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that management will be participating in fireside chats at the following upcoming investor conferences:

globenewswire.com - 2026-05-05 07:30:00

CAMBRIDGE, Mass., May 01, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on May 1, 2026, it awarded inducement grants to 43 new employees under Intellia's 2024 Inducement Plan, as amended, as a material inducement to employment.

globenewswire.com - 2026-05-01 16:01:00

Intellia Therapeutics (NASDAQ: NTLA) highlighted top-line results from its Phase III HAELO trial evaluating lonvo-z, an investigational in vivo CRISPR-based gene-editing therapy for hereditary angioedema (HAE), and provided an update on regulatory progress during a company conference call. Company outlines lonvo-z strategy and HAE unmet need Chief Executive Officer John Leonard described the update as a

defenseworld.net - 2026-04-29 15:13:29

CAMBRIDGE, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced the pricing of an underwritten public offering of 16,744,187 shares of its common stock. The shares of common stock are being sold at a public offering price of $10.75 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $180 million, excluding any exercise of the underwriters' option to purchase additional shares. All of the securities in the offering are to be sold by Intellia. In addition, Intellia has granted the underwriters a 30-day option to purchase up to 2,511,628 additional shares of its common stock at the public offering price, less the underwriting discounts and commissions.

globenewswire.com - 2026-04-29 07:00:00

While the heyday of Cathie Wood's investment management is, for the time being, firmly in the past, the popular ARK Innovation ETF (ARKK) has been having a respectable run in the last 12 months and unveiled its latest series of bets as recently as April 28.

finbold.com - 2026-04-29 06:27:39

Intellia shares drop 4% despite phase III data meeting all endpoints. The company begins a rolling FDA filing.

zacks.com - 2026-04-28 14:06:11

CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that it has commenced an underwritten public offering of $150 million of shares of its common stock. Intellia also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the public offering. All of the shares in the proposed offering are to be sold by Intellia.

globenewswire.com - 2026-04-27 16:01:00

Intellia Therapeutics, Inc. (NTLA) Discusses Topline Phase 3 HAELO Trial Results for Lonvoguran Ziclumeran in Hereditary Angioedema Transcript

seekingalpha.com - 2026-04-27 15:11:47

Intellia Therapeutics Inc. (NASDAQ:NTLA) shares are up on Monday after the company announced a rolling BLA submission to the FDA for its gene-editing therapy, lonvo-z (NTLA-2002), which is aimed at treating hereditary angioedema.

benzinga.com - 2026-04-27 10:07:20

Stock futures are struggling this morning as investors await Magnificent Seven earnings and the Fed meeting

schaeffersresearch.com - 2026-04-27 09:11:00

Intellia ​Therapeutics said ‌on ​Monday ​its experimental ⁠therapy ​for ​a rare ​genetic ​disorder has met ‌the ⁠main goal ​in ​a ⁠late-stage ​study.

reuters.com - 2026-04-27 07:06:46

Biotechnology stocks have seen a spike in merger and acquisition (M&A) activity. In March 2026 alone, there were 10 deals valued at approximately $31.5 billion.

marketbeat.com - 2026-04-27 07:06:01

Intellia Therapeutics said its Crispr-based treatment for a rare swelling condition succeeded in a Phase 3 trial, a landmark for gene editing. The treatment uses Nobel Prize-winning Crispr technology to edit DNA and treat hereditary angioedema, a condition that causes potentially life-threatening swelling attacks.

cnbc.com - 2026-04-27 07:01:01

CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced it has initiated a rolling submission of a biologics license application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of lonvo-z (formerly known as NTLA-2002) for hereditary angioedema (HAE).

globenewswire.com - 2026-04-27 07:00:00

Phase 3 HAELO trial of lonvoguran ziclumeran (lonvo-z) met primary and all key secondary endpoints;  favorable safety and tolerability data observed Single dose of lonvo-z freed most patients from both attacks and ongoing therapy for six-month efficacy evaluation period, demonstrating its potential to be the first and only one-time HAE treatment Rolling biologics license application (BLA) submission initiated with the U.S. Food and Drug Administration (FDA); anticipate U.S. launch in the first half of 2027, if approved Intellia to host webcast today at 8:00 a.m. ET CAMBRIDGE, Mass.

globenewswire.com - 2026-04-27 07:00:00

CAMBRIDGE, Mass., April 24, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced the company will report topline clinical data from its global Phase 3 HAELO clinical trial of lonvoguran ziclumeran (lonvo-z) in hereditary angioedema (HAE) on Monday, April 27, 2026 and will host a webcast at 8:00 a.m. ET to discuss the data.

globenewswire.com - 2026-04-24 16:05:00

World's first Phase 3 readout for an in vivo CRISPR gene editing candidate Company to host webcast to discuss data at 8:00 a. m. ET on April 27, 2026 CAMBRIDGE, Mass. , April 24, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced the company will report topline clinical data from its global Phase 3 HAELO clinical trial of lonvoguran ziclumeran (lonvo-z) in hereditary angioedema (HAE) on Monday, April 27, 2026 and will host a webcast at 8:00 a.

globenewswire.com - 2026-04-24 16:05:00

Massachusetts Financial Services Co. MA bought a new position in Intellia Therapeutics, Inc. (NASDAQ: NTLA) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 35,398 shares of the company's stock, valued at approximately $318,000. A number of other institutional investors and

defenseworld.net - 2026-04-19 04:26:49

Intellia stock climbs nearly 20% in three months as pipeline progress, lifted FDA holds, and late-stage study updates boost investor optimism.

zacks.com - 2026-04-16 10:36:07

Zoetis has strong growth prospects and an attractive income program. BioNTech has a rich pipeline that could help jolt the stock as it makes clinical progress.

fool.com - 2026-04-15 17:00:00